Since most conventional serum markers are CAs produced from protein glycosylation catalyzed by GalNAc-Ts [44, 45], GalNAc-T6 is a candidate biomarker could be applied clinically in combination with these conventional tumor markers. Here, B4GALNT1 is linked to neoplasm.